N-[3-(二甲氨基)丙基]-N-甲基乙酰胺 | 61877-76-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[3-(二甲氨基)丙基]-N-甲基乙酰胺
• 英文名称: N-[3-(dimethylamino)propyl]-N-methylacetamide
• 英文别名: N-methyl-N-(3-dimethylamino-propyl)-acetamide
• CAS: 61877-76-7
• 化学式: C₈H₁₈N₂O
• 分子量: 158.244
• InChiKey: YYFXTUNVEIMPBU-UHFFFAOYSA-N

物化性质

• 沸点：
  230.3±23.0 °C(Predicted)
• 密度：
  0.918±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲基-1,3-丙二胺 在 乙酸酐 作用下， 以 丙酮 为溶剂， 以76.6%的产率得到N-[3-(二甲氨基)丙基]-N-甲基乙酰胺
  参考文献：
  名称：

  Odorless catalysts for the synthesis of polyurethanes

  摘要：

  该即时发明涉及新颖化合物及其在生产聚氨酯树脂中的应用。这些化合物通常对应以下公式：##STR1##其中n是1到5之间的整数，R是C.sub.1 -C.sub.5烷基，Y是C.sub.1 -C.sub.5烷基或者##STR2##，Z是##STR3##其中n=0或1，X是--O--或者##STR4##，R'是具有1到15个碳原子的脂肪基，可能含有酯、醚或酰胺基团或者三级氮，当m=0时，R'可能是氢原子。

  公开号：

  US04348536A1

文献信息

• A mechanically strong and tough anion exchange membrane engineered with non-covalent modalities
  作者：Xiaojuan Wang、Ping Wang、Yiyan Sun、Jinlei Wang、Huagao Fang、Shanzhong Yang、Haibing Wei、Yunsheng Ding

  DOI：10.1039/c7cc07284h

  日期：——

  tough anion exchange membrane was constructed using the strategy of supramolecular modalities. After introducing a secondary amide as a hydrogen-bonding crosslinking motif into the side chain of the PPO backbone, the membrane exhibits high mechanical strength and excellent flexibility (101% elongation at break), as well as suppressed water uptake, enhanced thermal stability and good fuel cell performances

  使用超分子模态的策略构建了一种机械坚固且坚韧的阴离子交换膜。将二级酰胺作为氢键交联基序引入PPO主链的侧链后，该膜表现出较高的机械强度和出色的柔韧性（101％的断裂伸长率），并且抑制了水的吸收，增强了热稳定性，并具有良好的耐热性。燃料电池性能。
• Benzimidazole and Pyridylimidazole Derivatives
  申请人：Li Guiying

  公开号：US20080227793A1

  公开（公告）日：2008-09-18

  This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA A receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABA A receptors in tissue sections.

  本发明涉及苯并咪唑、吡啶咪唑和相关的双环杂芳烃化合物，所有这些化合物都可以用公式I描述。本发明特别涉及与GABAA受体的苯二氮卓位点具有高选择性和高亲和力的这种化合物。本发明还涉及包含这种化合物的制药组合物以及在治疗某些中枢神经系统（CNS）疾病中使用这种化合物的用途。还公开了制备公式I化合物的新方法。本发明还涉及将公式I的苯并咪唑、吡啶咪唑和相关的双环杂芳烃化合物与一个或多个其他CNS药剂联合使用以增强其他CNS药剂的效果。此外，本发明还涉及将这些化合物用作定位组织切片中的GABAA受体的探针。
• Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
  申请人：Connolly Joseph Terrence

  公开号：US20070265446A1

  公开（公告）日：2007-11-15

  Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R 5 and R 10 are as defined herein.

  公式I所代表的化合物：它们可用作α-1A/B肾上腺素受体拮抗剂，用于治疗与α-1A/B肾上腺素受体活性相关的疾病的方法，以及制备该化合物的方法，其中Ar、Z、R、R′、R5和R10如本文所定义。
• Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them
  申请人：FOULON Loic

  公开号：US20070203184A1

  公开（公告）日：2007-08-30

  The present invention relates to novel indolin-2-one derivatives of formula: to the preparation and to the pharmaceutical compositions comprising them. These compounds have an affinity for oxytocin receptors.

  本发明涉及公式为的新型吲哚啉-2-酮衍生物、其制备方法以及包含它们的药物组合物。这些化合物具有与催产素受体的亲和力。
• MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：US20130230582A1

  公开（公告）日：2013-09-05

  Drug derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drug derivatized with a weak-base moiety that facilitates active loading of the drug through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drug to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drug derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drugs.

  本文提供了适用于装载到脂质体纳米粒载体中的药物衍生物。在一些首选方面中，这些衍生物包括一种水溶性差的药物，其衍生物化为一种弱碱基团，通过LN跨膜pH或离子梯度促进药物的活性装载到LN的水性内部。弱碱基团可以选择性地包括一个亲脂性结构域，以促进药物的活性装载到脂质体膜的内单层。优点是，药物衍生物的LN配方相对于相应的游离药物表现出改善的溶解度、降低的毒性、增强的疗效和/或其他益处。